JP2017533891A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533891A5
JP2017533891A5 JP2017516489A JP2017516489A JP2017533891A5 JP 2017533891 A5 JP2017533891 A5 JP 2017533891A5 JP 2017516489 A JP2017516489 A JP 2017516489A JP 2017516489 A JP2017516489 A JP 2017516489A JP 2017533891 A5 JP2017533891 A5 JP 2017533891A5
Authority
JP
Japan
Prior art keywords
domain
seq
amino acid
acid sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017516489A
Other languages
English (en)
Japanese (ja)
Other versions
JP6839075B2 (ja
JP2017533891A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/051314 external-priority patent/WO2016048938A1/en
Publication of JP2017533891A publication Critical patent/JP2017533891A/ja
Publication of JP2017533891A5 publication Critical patent/JP2017533891A5/ja
Application granted granted Critical
Publication of JP6839075B2 publication Critical patent/JP6839075B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017516489A 2014-09-26 2015-09-22 Cd19及びcd3に結合できる二重特異性1価ダイアボディ並びにその使用 Active JP6839075B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055695P 2014-09-26 2014-09-26
US62/055,695 2014-09-26
PCT/US2015/051314 WO2016048938A1 (en) 2014-09-26 2015-09-22 Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof

Publications (3)

Publication Number Publication Date
JP2017533891A JP2017533891A (ja) 2017-11-16
JP2017533891A5 true JP2017533891A5 (cg-RX-API-DMAC7.html) 2018-11-01
JP6839075B2 JP6839075B2 (ja) 2021-03-03

Family

ID=55581876

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017516489A Active JP6839075B2 (ja) 2014-09-26 2015-09-22 Cd19及びcd3に結合できる二重特異性1価ダイアボディ並びにその使用

Country Status (29)

Country Link
US (4) US10633443B2 (cg-RX-API-DMAC7.html)
EP (1) EP3197917B1 (cg-RX-API-DMAC7.html)
JP (1) JP6839075B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170063755A (cg-RX-API-DMAC7.html)
CN (1) CN107484416A (cg-RX-API-DMAC7.html)
AP (1) AP2017009823A0 (cg-RX-API-DMAC7.html)
AR (1) AR101997A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015321546B2 (cg-RX-API-DMAC7.html)
CA (1) CA2962603A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017000711A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017002793A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170109A (cg-RX-API-DMAC7.html)
CU (1) CU20170041A7 (cg-RX-API-DMAC7.html)
DO (1) DOP2017000083A (cg-RX-API-DMAC7.html)
EA (1) EA201790719A1 (cg-RX-API-DMAC7.html)
ES (1) ES2935062T3 (cg-RX-API-DMAC7.html)
IL (1) IL251377B (cg-RX-API-DMAC7.html)
MA (1) MA40573A (cg-RX-API-DMAC7.html)
MD (1) MD20170040A2 (cg-RX-API-DMAC7.html)
MX (1) MX375669B (cg-RX-API-DMAC7.html)
NI (1) NI201700037A (cg-RX-API-DMAC7.html)
PE (1) PE20170894A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500544A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201702310QA (cg-RX-API-DMAC7.html)
TN (1) TN2017000106A1 (cg-RX-API-DMAC7.html)
TW (1) TWI706960B (cg-RX-API-DMAC7.html)
UY (1) UY36316A (cg-RX-API-DMAC7.html)
WO (1) WO2016048938A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701985B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
CU20170041A7 (es) * 2014-09-26 2017-09-06 Macrogenics Inc Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3
US10717778B2 (en) 2014-09-29 2020-07-21 Duke University Bispecific molecules comprising an HIV-1 envelope targeting arm
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
IL267485B2 (en) 2016-12-21 2024-01-01 Teneobio Inc Anti-bcma heavy chain-only antibodies and uses thereof
CA3053803A1 (en) 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
MA50185A (fr) 2017-09-22 2020-07-29 Wuxi Biologics Ireland Ltd Nouveaux complexes polypeptidiques cd3/cd19 bispécifiques
KR102839644B1 (ko) 2017-09-22 2025-07-31 우시 바이올로직스 아일랜드 리미티드 신규한 이중특이적 폴리펩티드 복합체
WO2019064263A1 (en) * 2017-09-29 2019-04-04 Janssen Biotech, Inc. NOVEL FORMULATIONS FOR STABILIZING LOW DOSE ANTIBODY COMPOSITIONS
CN109706163A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用
CN109957026A (zh) * 2017-12-22 2019-07-02 成都恩沐生物科技有限公司 共价多特异性抗体
EP3752196A4 (en) * 2018-02-15 2022-03-23 MacroGenics, Inc. CD3-BINDING DOMAIN VARIANTS AND THEIR USE IN COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES
SG11202011597RA (en) * 2018-07-20 2020-12-30 Teneobio Inc Heavy chain antibodies binding to cd19
CN109402168A (zh) * 2018-10-30 2019-03-01 深圳新诺微环生物科技有限公司 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用
BR112021008486A2 (pt) * 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
CN113396161A (zh) * 2018-12-04 2021-09-14 诺华股份有限公司 针对cd3的结合分子及其用途
CN114341176A (zh) * 2019-04-08 2022-04-12 纪念斯隆凯特琳癌症中心 Cd19抗体及其使用方法
KR102878895B1 (ko) 2019-05-21 2025-10-31 노파르티스 아게 Cd19 결합 분자 및 이의 용도
CN116987197A (zh) * 2019-06-20 2023-11-03 成都恩沐生物科技有限公司 共价多特异性抗体
KR20220144821A (ko) 2020-02-21 2022-10-27 마크로제닉스, 인크. Cd137 결합 분자 및 그것의 용도
KR20230157315A (ko) 2021-01-28 2023-11-16 리제너론 파마슈티칼스 인코포레이티드 사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법
CN113488112A (zh) * 2021-06-10 2021-10-08 五邑大学 一种共价结合预测方法及装置
CA3231761A1 (en) * 2021-09-13 2023-03-16 Qiong Wang Anti-human cd3 antibody and use thereof
IL316002A (en) 2022-04-11 2024-11-01 Regeneron Pharma Compositions and methods for universal tumor cell killing
EP4665385A2 (en) 2023-02-17 2025-12-24 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
WO1991003493A1 (en) 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
AU666852B2 (en) 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
JPH10511957A (ja) 1995-01-05 1998-11-17 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン 表面改質ナノ微粒子並びにその製造及び使用方法
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5916597A (en) 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
JP2000506165A (ja) 1996-03-04 2000-05-23 ザ ペン ステイト リサーチ ファウンデーション 細胞インターナリゼーションを増強するための物質および方法
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
PT954282E (pt) 1997-01-16 2005-06-30 Massachusetts Inst Technology Preparacao de particulas para inalacao
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
ITRM20010408A1 (it) 2001-07-10 2003-01-10 Univ Napoli Federico Ii Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US9296816B2 (en) 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101410521B1 (ko) 2005-12-16 2014-06-20 아이비씨 파마슈티컬스, 인코퍼레이티드 다가 면역글로불린-계 생동성 어셈블리들
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
AU2008265984B2 (en) 2007-06-21 2014-07-17 Macrogenics, Inc. Covalent diabodies and uses thereof
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
WO2010028797A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028795A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028796A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Trispecific hexavalent antibodies
MX2011006416A (es) 2008-12-19 2011-07-12 Macrogenics Inc Diacuerpos covalentes y sus usos.
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
BRPI1007602A2 (pt) 2009-05-27 2016-02-16 Hoffmann La Roche "anticorpo tri ou tetraespecífico, método para preparação de um anticorpo triespecífico ou tetraespecífico, célula hospedeira, composição, composição farmacêutica e método para o tratamento de um paciente com necessidade de terapia"
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
EP2525820B1 (en) * 2010-01-19 2016-05-11 Immunomedics, Inc. Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
US20110206672A1 (en) * 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
RU2624027C2 (ru) 2010-04-23 2017-06-30 Дженентек, Инк. Получение гетеромультимерных белков
EP2601216B1 (en) 2010-08-02 2018-01-03 MacroGenics, Inc. Covalent diabodies and uses thereof
WO2012156430A1 (en) 2011-05-17 2012-11-22 Trion Research Gmbh Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
CN107722124A (zh) * 2011-05-21 2018-02-23 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
ES2605784T3 (es) * 2011-05-21 2017-03-16 Macrogenics, Inc. Dominios de enlazamiento a suero desinmunizados y su uso para extender la vida media en suero
WO2012162583A1 (en) 2011-05-26 2012-11-29 Ibc Pharmaceuticals, Inc. Design and construction of novel multivalent antibodies
US20150045540A1 (en) 2011-06-28 2015-02-12 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
EP2729488A4 (en) 2011-07-06 2015-01-14 Medimmune Llc PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
UA118833C2 (uk) * 2011-08-17 2019-03-25 Ґлаксо Ґруп Лімітед Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1
AU2013216943B2 (en) 2012-02-10 2018-04-19 Research Corporation Technologies, Inc. Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
WO2013174873A1 (en) 2012-05-24 2013-11-28 F. Hoffmann-La Roche Ag Multispecific antibodies
JP2015528003A (ja) * 2012-07-13 2015-09-24 ザイムワークス,インコーポレイテッド 抗cd3構築物を含む二重特異性の非対称ヘテロ二量体
WO2014022540A1 (en) 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
EP2938637A2 (en) 2012-12-28 2015-11-04 AbbVie Inc. Multivalent binding protein compositions
HRP20191865T1 (hr) 2013-01-14 2020-01-10 Xencor, Inc. Novi heterodimerni proteini
LT2951203T (lt) 2013-03-15 2019-09-10 Xencor, Inc. Heterodimeriniai baltymai
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) * 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
RU2718692C2 (ru) * 2014-05-29 2020-04-13 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
TWI693232B (zh) * 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CU20170041A7 (es) * 2014-09-26 2017-09-06 Macrogenics Inc Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3
US10717778B2 (en) * 2014-09-29 2020-07-21 Duke University Bispecific molecules comprising an HIV-1 envelope targeting arm
SG11201706024YA (en) 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains
EP3337507A4 (en) * 2015-08-17 2019-04-24 MacroGenics, Inc. BIS-SPECIFIC MONOVALENTS DIABODIES WITH ABILITY TO BIND B7-H3 AND CD3 AND USES THEREOF
TW201720458A (zh) * 2015-12-04 2017-06-16 宏觀基因股份有限公司 能夠結合cd19 和cd3 的雙特異性單價雙抗體以及其用途
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
EP3464378A4 (en) * 2016-06-07 2020-06-17 MacroGenics, Inc. METHOD FOR USE OF CD32B X CD79B BINDING MOLECULES IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS
CA3053803A1 (en) * 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
BR112020011810A2 (pt) * 2017-12-12 2020-11-17 Macrogenics, Inc. molécula de ligação cd16 x antígeno de doença, composição farmacêutica, uso da composição farmacêutica, e método para o tratamento de uma doença
EP3752196A4 (en) * 2018-02-15 2022-03-23 MacroGenics, Inc. CD3-BINDING DOMAIN VARIANTS AND THEIR USE IN COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES
JP2021524451A (ja) * 2018-05-18 2021-09-13 マクロジェニクス,インコーポレーテッド 最適化済みgp41結合分子及びその使用

Similar Documents

Publication Publication Date Title
JP2017533891A5 (cg-RX-API-DMAC7.html)
JP2017504577A5 (cg-RX-API-DMAC7.html)
US20210163564A1 (en) FUSION PROTEINS COMPRISING A BINDING PROTEIN AND AN INTERLEUKIN-15 POLYPEPTIDE HAVING A REDUCED AFFINITY FOR IL15Ra AND THERAPEUTIC USES THEREOF
JP2024099850A5 (cg-RX-API-DMAC7.html)
FI3946621T3 (fi) Mage a4 -t-solureptoreja
JP2016525551A5 (cg-RX-API-DMAC7.html)
HRP20220553T1 (hr) Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela
HRP20161656T4 (hr) Sredstva za vezanje na cd33
JP2019531725A5 (cg-RX-API-DMAC7.html)
JP2018504143A5 (cg-RX-API-DMAC7.html)
JP2018503380A5 (cg-RX-API-DMAC7.html)
HRP20160422T1 (hr) Protutijela protiv flt3 postupci njihove upotrebe
JP2020501531A5 (cg-RX-API-DMAC7.html)
JP2019524693A5 (cg-RX-API-DMAC7.html)
JP2017537620A5 (cg-RX-API-DMAC7.html)
JP2013515472A5 (cg-RX-API-DMAC7.html)
JP2010532169A5 (cg-RX-API-DMAC7.html)
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
JP2017527272A5 (cg-RX-API-DMAC7.html)
JP2013527761A5 (cg-RX-API-DMAC7.html)
JP2019535306A5 (cg-RX-API-DMAC7.html)
JP2009539380A5 (cg-RX-API-DMAC7.html)
JP2010535032A5 (cg-RX-API-DMAC7.html)
CA2798390A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
JP2018501208A5 (cg-RX-API-DMAC7.html)